Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...

Researchers’ understanding of the pathogenesis of rheumatoid arthritis has grown considerably in recent years, laying the ...

In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

The theory behind leucovorin's use for autism postulates that some children have a blockage in the transport of folic acid into the brain that potentially contributes to neurological symptoms.

Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

HOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

LONDON - Oncimmune Holdings PLC (AIM: ONC.L), a company specializing in autoantibody profiling for the pharmaceutical and biotechnology sectors, has announced the scheduling of a General Meeting (GM) ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Indian scientists have created an innovative self-actuating drug delivery system for Rheumatoid Arthritis, providing precise ...